文献速递乳腺癌

新辅助化疗后乳腺癌局部区域复发风险的汇总分析

Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials.
PubMed 文献 · Eur J Cancer · 2020-03-13

该汇总分析纳入九项新辅助试验的10,075例原发性乳腺癌患者,中位随访67个月,总体局部区域复发率为9.5%,pCR患者为4.1%。多因素分析显示年轻、临床淋巴结阳性、G3肿瘤、non-pCR和TNBC是独立预测因素,手术方式无关。

要点

  • 新辅助化疗后总体LRR率为9.5%,pCR患者仅4.1%。
  • 年轻、淋巴结阳性、G3、non-pCR和TNBC为独立LRR预测因素。
  • non-pCR的TNBC和HR-/HER2+患者LRR风险显著高于HR+/HER2-。

核心结论

  • 年轻、淋巴结阳性、G3肿瘤、TNBC及non-pCR显著增加新辅助化疗后局部区域复发风险。

研究设计与样本

  • 汇总分析纳入九项前瞻性新辅助乳腺癌试验的10,075例原发性乳腺癌女性。
  • 主要终点为局部区域复发作为新辅助化疗后首个事件,远处复发、第二恶性肿瘤或死亡为竞争事件。

主要发现

  • 中位随访67个月(范围0-215),总体LRR率为9.5%,pCR患者为4.1%而非pCR为9.5%。
  • 多因素分析中年轻、临床淋巴结阳性、G3肿瘤、non-pCR和TNBC是独立LRR预测因素,手术方式不是。
  • 5年累积LRR率在non-pCR vs pCR中:HR+/HER2-为5.9% vs 3.9%(HR=2.32,95%CI 1.22-4.43,p=0.011)。
  • HR-/HER2+为14.8% vs 3.1%(HR=4.26,95%CI 2.35-7.71,p<0.001)。
  • TNBC为18.5% vs 4.2%(HR=4.10,95%CI 2.88-5.82,p<0.001);HR+/HER2+为8.1% vs 4.8%(HR=1.56,95%CI 0.85-2.85,p=0.150)。

关键数值与推荐

  • non-pCR亚组内,HR-/HER2+和TNBC相比HR+/HER2-的LRR风险更高,HR分别为2.05(95%CI 1.54-2.73,p<0.001)和2.77(95%CI 2.27-3.39,p<0.001)。

临床怎么用

  • 对新辅助化疗后non-pCR且携带年轻、淋巴结阳性、G3、TNBC或HR-/HER2+特征的高危患者,需探索更优的多模式术后治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: This pooled analysis aimed to evaluate locoregional recurrence (LRR) rates of breast cancer (BC) after neoadjuvant chemotherapy (NACT) and to identify independent LRR predictors. METHODS: 10,075 women with primary BC from nine neoadjuvant trials were included. The primary outcome was the cumulative incidence rate of LRR as the first event after NACT. Distant recurrence, secondary malignancy or death were defined as competing events. For identifying LRR predictors, surgery type, pathological complete response (pCR), BC subtypes and other potential risk factors were evaluated. RESULTS: Median followup was 67 months (range 0-215), overall LRR rate was 9.5%, 4.1% in pCR versus 9.5% in non-pCR patients. Younger age, clinically positive lymph nodes, G3 tumours, non-pCR and TNBC but not surgery type were independent LRR predictors in multivariate analysis. Among BC subtypes, 5-year cumulative LRR rates were associated with higher risk in non-pCR versus pCR patients, which was significant for HR+/HER2- (5.9% vs 3.9%; HR = 2.32 [95%CI 1.22-4.43]; p = 0.011); HR-/HER2+ (14.8% vs 3.1%; HR = 4.26 [94%CI 2.35-7.71]; p < 0.001) and TNBC (18.5% vs 4.2%; HR = 4.10 [95%CI 2.88-5.82]; p < 0.001) but not for HR+/HER2+ (8.1% vs 4.8%; HR = 1.56 [95%CI 0.85-2.85]; p = 0.150). Within non-pCR subgroup, LRR risk was higher for HR-/HER2+ and TNBC vs HR+/HER2- (HR = 2.05 [95%CI 1.54-2.73]; p < 0.001 and HR = 2.77 [95%CI 2.27-3.39]; p < 0.001, respectively). CONCLUSIONS: This pooled analysis demonstrated that young age, node-positive and G3 tumours, as well as TNBC, and non-pCR significantly increased the risk of LRR after NACT. Hence, there is a clear need to investigate better multimodality therapies in the post-neoadjuvant setting for high-risk patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Werutsky G, Untch M, Hanusch C, et al. Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials. Eur J Cancer. 2020. PMID: 32179450. doi:10.1016/j.ejca.2020.02.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。